AstraZeneca granted U.K. approval for its Covid-19 vaccine

AstraZeneca granted U.K. approval for its Covid-19 vaccine

LONDON — In more promising news in the fight against Covid-19, the British drugmaker AstraZeneca’s vaccine candidate has received regulatory approval in the United Kingdom.

The vaccine was made in collaboration with U.K.’s Oxford University and comes three weeks after the U.K. became the first nation to roll out the Pfizer-BioNTech vaccine.

The vaccine is considered vital for vaccination efforts in developing countries because it is cheaper to make and easier to store for long periods of time as it only requires normal refrigeration temperature to remain viable, making distribution easier.

Prime Minister Boris Johnson hailed the news as a “triumph for British science.”

“With two vaccines now approved, we will be able to vaccinate a greater number of people who are at highest risk, protecting them from the disease and reducing mortality and hospitalization,” The U.K.’s Department of Health said in a statement.

The statement cautioned, however, that social distancing and hand washing are still vital to suppress the infection while people across the country wait to receive the vaccines.

Professor Andrew Pollard, director of the Oxford Vaccine Group, said: “Though this is just the beginning, we will start to get ahead of the pandemic, protect health and economies when the vulnerable are vaccinated everywhere, as many as possible as soon possible.”

Pascal Soriot, CEO of AstraZeneca, said: “Today is an important day for millions of people in the UK who will get access to this new vaccine. It has been shown to be effective, well-tolerated, simple to administer and is supplied by AstraZeneca at no profit.”

British Health Secretary Matt Hancock said the first doses would be administered from Jan. 4.

The U.K. is in the midst of a serious spike in Covid-19 infections, with a record 53,000 confirmed on Tuesday. Hospitals across the country are filling up with Covid patients, amid fears that some intensive care units cannot cope.

This month, the Oxford vaccine became the first to have its Phase 3 clinical trial results published in a peer-reviewed medical journal, the Lancet, which confirmed the initial findings that the shots have an average effectiveness of 70.4 percent.

Peer-reviewed data, which experts have been desperate to see, showed there were no hospitalizations or cases of severe Covid-19 three weeks after the first doses were administered to around 11,600 volunteers in the U.K. and Brazil.

Last month, Oxford University researchers released results from its Phase 3 trial, including one surprising detail: Some trial volunteers received a lower first dose of the vaccine, but appeared to have a higher protection — 90 percent — against symptomatic Covid-19.

Volunteers who received standard double-dose regimen received around 62 percent protection, it said. Combining the two gave the average of around 70 percent.

Download the NBC News app for breaking news and politics

But questions were raised after it emerged that the lower dose was administered by mistake — something the officials and scientists failed to mention when presenting their findings.

U.K.’s Department of Health said its priority was to give as many vulnerable people as possible a first dose “rather than providing the required two doses in as short a time as possible.”

The department added that everyone receiving the vaccination will still receive their second dose within 12 weeks of their first to ensure longer-term protection.

Once seen as the front-runner in the development of a coronavirus vaccine, the AstraZeneca-Oxford team was overtaken by Pfizer and its German partner BioNTech, whose shots were rolled out in Britain and the United States this month.

However, AstraZeneca’s vaccine has received considerable support even before it was authorized.

The U.S. federal government has ordered 300 million doses of the vaccine and pledged up to $1.2 billion to support its research and development. Meanwhile, the U.K. has also secured access to 100 million doses, with up to 4 million doses expected to be ready by the end of the year.

Full coverage of the coronavirus outbreak

Another difficulty faced by vaccine makers is whether their candidate will measure up against a new coronavirus variant, first detected in England and now spreading globally, that can make the virus up to 70 percent more infectious.

Last week, AstraZeneca said its vaccine should be effective against the new variant, but studies were under way to fully investigate the impact of the mutation.

Reuters contributed to this report.

Image: Yuliya TalmazanYuliya Talmazan

Yuliya Talmazan is a London-based journalist.

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *